Bridgeway Capital Management LLC Purchases New Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Bridgeway Capital Management LLC acquired a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 140,000 shares of the company's stock, valued at approximately $658,000. Bridgeway Capital Management LLC owned about 0.26% of Fulcrum Therapeutics as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. MetLife Investment Management LLC boosted its stake in shares of Fulcrum Therapeutics by 145.8% during the fourth quarter. MetLife Investment Management LLC now owns 40,107 shares of the company's stock valued at $189,000 after purchasing an additional 23,792 shares during the period. Barclays PLC increased its stake in shares of Fulcrum Therapeutics by 367.1% during the third quarter. Barclays PLC now owns 124,141 shares of the company's stock valued at $443,000 after buying an additional 97,565 shares during the period. American Century Companies Inc. raised its holdings in shares of Fulcrum Therapeutics by 5.9% in the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock valued at $567,000 after acquiring an additional 6,770 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Fulcrum Therapeutics by 34.4% during the 4th quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock worth $161,000 after acquiring an additional 8,761 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Fulcrum Therapeutics by 176.8% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company's stock valued at $1,728,000 after purchasing an additional 234,810 shares during the period. 89.83% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "neutral" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $8.63.

Fulcrum Therapeutics Stock Down 0.7%

NASDAQ FULC opened at $5.37 on Monday. Fulcrum Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $10.13. The company has a 50 day moving average price of $3.38 and a 200 day moving average price of $3.70. The firm has a market cap of $289.87 million, a PE ratio of -17.32 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. On average, equities research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.